Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively
Hence, combining microglial targeting with supportive interventions on neuronal or astrocytic function may ultimately be necessary to achieve lasting neuroprotection
OptumRx, 2026 formulary update and prior authorization criteria In February 2026, OptumRx removed the BMI requirement from its cardiovascular reauthorization criteria for Wegovy, simplifying continued authorization for UHC members using the CV indication
This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications
Melatonin further reinforces insulin sensitivity by synchronizing circadian insulin secretion, improving mitochondrial efficiency in hepatocytes and skeletal muscle, and attenuating the nocturnal cortisol overshoot typical in PCOS (226, 227)
